Evidence map›Paper›PMID 36994051›Full record

ArticleJournal of family medicine and primary care2022

Evaluation of the effectiveness of triamcinolone solution diluted with normal saline for the treatment of seborrheic dermatitis.

Fatemeh Jamali, Danyal Daneshdoust

Open access · goldAbstract read
In one paragraph

Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Fatemeh JamaliGeneral Physician, Aesthetic Field, Qazvin, Iran.
Danyal DaneshdoustDepartment of Dermatology, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
Babol University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: Seborrheic dermatitis is a common inflammatory disease for which various treatments have been proposed. The main purpose of this study was to determine the effectiveness of 80-mg Triamcinolone solution diluted with 0.1% normal saline for the treatment of seborrheic dermatitis in adults. Methods: For this study, 120 patients with seborrheic dermatitis were considered. After obtaining written and informed consent, patients were treated with 80 mg of Triamcinolone diluted with 0.1% normal saline. To evaluate the effectiveness of Triamcinolone treatment, the scoring index (SI) and the level of patient satisfaction were evaluated at 2 and 4 weeks after the start of treatment and also 4 weeks after the end of treatment. Results: The results of the study showed that 61.67% (74 patients) were satisfied with "good" to "very good" for the Triamcinolone treatment to seborrheic dermatitis. Based on the findings of the study, it was found that the SI before treatment was equal to 2.45 ± 7.45, which after 2 weeks after treatment, this index decreased by 61.6% (SI: 2.86 ± 1.94). In addition, the SI decreased to 88.6% (SI: 0.85 ± 1.02) after 4 weeks. Conclusion: Considering the high decrease in SI, increasing patient satisfaction and observing a low number of cases with recurrence of the disease by Triamcinolone treatment method, it can be concluded that injection of Triamcinolone 80 mg diluted with 0.1% normal saline can be effective and efficient for the treatment of seborrheic dermatitis.

Indexed as

Corticosteroidsscoring indexseborrheic dermatitistriamcinolone

Identifiers

PMID36994051
PMCPMC10040996
OpenAlexW4320154691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.